Protection of salivary function by intensity-modulated radiation therapy in patients with head and neck cancer

Seminars in Radiation Oncology

Volumn 12, Issue 1 SUPPL. 1, 2002, Pages 20-25

  Clifford Chao, K S ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; DRUG METABOLITE; MESNA; RAZOXANE; UNCLASSIFIED DRUG; WR 1605;

CANCER CONTROL; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; DOSE RESPONSE; DOSIMETRY; DRUG EFFECT; DRUG MECHANISM; HEAD CANCER; HUMAN; HYPOTENSION; NAUSEA; NECK CANCER; OROPHARYNX CARCINOMA; PRIORITY JOURNAL; RADIATION DOSE; RADIATION EXPOSURE; RADIATION PROTECTION; RASH; SALIVARY GLAND; SALIVATION; XEROSTOMIA;

EID: 0036127726     PISSN: 10534296     EISSN: None     Source Type: Journal    
DOI: 10.1053/srao.2002.31359     Document Type: Conference Paper

References (25)

1. Late effects of radiation therapy in the head and neck region
2. Detailed quality of life assessment in patients treated with primary radiotherapy for cancer of the base of the tongue
3. Quality of life in patients treated for head and neck cancer. A follow-up study 7 to 11 years after radiotherapy
4. Influence of late side-effects upon daily life after radiotherapy for laryngeal and pharyngeal cancer
5. A return to "normal eating" after curative treatment for oral cancer. What are the long term prospects?
6. Osteoradionecrosis of the mandible: A review
7. Chronic xerostomia increases esophageal acid exposure and is associated with esophageal injury
8. Oral pilocarpine for post-irradiation xerostomia in patients with head and neck cancer
9. Preliminary results of a pilot study using WR-2721 before fractionated irradiation of the head and neck to reduce salivary gland dysfunction
10. Final results of a phase III randomized trial of amifostine as a radioprotector in head and neck cancer
11. Parotid gland function during and following radiotherapy of malignancies in the head and neck: A consecutive study of salivary flow and patient discomfort
12. Some factors influencing salivary function when treating with radiotherapy
13. Dose, volume, and function relationships in parotid salivary glands following conformal and intensity-modulated irradiation of head and neck cancer
14. A prospective study of salivary function sparing in patients with head-and-neck cancers receiving intensity-modulated or three-dimensional radiation therapy: Initial results
15. Intensity modulated radiation therapy in head and neck cancers: The Mallinckrodt experience
16. Intensity-modulated radiation therapy reduces late salivary toxicity without compromising tumor control in patients with oropharyngeal carcinoma: A comparison with conventional techniques
17. Parotid gland sparing in patients undergoing bilateral head and neck irradiation: Techniques and early results
18. Comprehensive irradiation of head and neck cancer using conformal multisegmental fields: Assessment of target coverage and noninvolved tissue sparing
19. Smart (simultaneous modulated accelerated radiation therapy) boost: A new accelerated fractionation schedule for the treatment of head and neck cancer with intensity modulated radiotherapy
20. 3-D intensity modulated radiotherapy (IMRT) in the treatment of nasopharyngeal carcinoma: The UCSF experience
21. Assessment of xerostomia-related quality of life in head and neck cancer patients receiving comprehensive radiation using parotid sparing techniques
22. The current status of WR-2721 (amifostine): A chemotherapy and radiation therapy protector
23. Chemical modifiers of cancer treatment
24. Pharmacokinetics of amifostine: Effects of dose and method of administration
25. Subcutaneous administration of amifostine during fractionated radiotherapy: A randomized phase II study